Chennai hospital unique honour from Intellectual Property India

Prof M Viswanathan Diabetes Research Centre, Royapuram, Chennai received an exclusive patent rights from the Intellectual Property India, Government of India for developing a unique footwear for people with diabetes. The grant of the Patent is an honor and recognition for Prof M Viswanathan Diabetes Research Centre, Royapuram to its continued dedication in the field of diabetic research.

The patent demonstrates the innovative approach in developing exclusive footwear especially for diabetes patients. It reduces the risk of several foot problems related with diabetes and helps to prevent complications including strain, ulcers and amputations in people with diabetes. This exclusive diabetic footwear offers pressure reduction under the foot while walking and is particularly useful for people with Diabetes with neuropathy and loss of sensation in their feet.

Dr. Vijay Viswanathan, Head and Chief Diabetologist, M.V. Hospital for Diabetes and Prof. M Viswanathan Diabetes Research Centre, Royapuram, Chennai said, “It is rare for a hospital for Diabetes to get a patent for developing a product. The patent has been given by Intellectual Property India, Govt. of India for developing a unique preventive footwear for people with Diabetes, who at risk of developing foot complications.

Prof. M Viswanathan Diabetes Foot Research Centre, Royapuram, Chennai has been actively involved in Diabetes research since 1972 and has published more than 1000 research papers in this field. MV Hospital for Diabetes, Royapuram has successfully prevented a major amputation in more than 80,000 patients in the past 28 years.” M V Hospital for Diabetes at Royapuram Chennai established in 1954, has been in the fore front of providing a comprehensive care for saving the feet of people with Diabetes. Recently, M. V Hospital for Diabetes and Prof M Viswanathan Diabetes Research Centre Royapuram Chennai had been re-designated as WHO Collaborating Centre for Research, Education and Training in Diabetes for the 5th consecutive time since 2002.